These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 9407971)
1. Abrogation of wild-type p53-mediated transactivation is insufficient for mutant p53-induced immortalization of normal human mammary epithelial cells. Cao Y; Gao Q; Wazer DE; Band V Cancer Res; 1997 Dec; 57(24):5584-9. PubMed ID: 9407971 [TBL] [Abstract][Full Text] [Related]
2. Mutant p53-induced immortalization of primary human mammary epithelial cells. Gao Q; Hauser SH; Liu XL; Wazer DE; Madoc-Jones H; Band V Cancer Res; 1996 Jul; 56(13):3129-33. PubMed ID: 8674072 [TBL] [Abstract][Full Text] [Related]
3. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells. Davis P; Bazar K; Huper G; Lozano G; Marks J; Iglehart JD Oncogene; 1996 Sep; 13(6):1315-22. PubMed ID: 8808706 [TBL] [Abstract][Full Text] [Related]
4. Immortalization of human mammary epithelial cells transfected with mutant p53 (273his). Gollahon LS; Shay JW Oncogene; 1996 Feb; 12(4):715-25. PubMed ID: 8632893 [TBL] [Abstract][Full Text] [Related]
5. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Forrester K; Lupold SE; Ott VL; Chay CH; Band V; Wang XW; Harris CC Oncogene; 1995 Jun; 10(11):2103-11. PubMed ID: 7784055 [TBL] [Abstract][Full Text] [Related]
6. Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Yang G; Rosen DG; Mercado-Uribe I; Colacino JA; Mills GB; Bast RC; Zhou C; Liu J Carcinogenesis; 2007 Jan; 28(1):174-82. PubMed ID: 16829690 [TBL] [Abstract][Full Text] [Related]
7. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations. Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393 [TBL] [Abstract][Full Text] [Related]
8. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Dimri GP; Martinez JL; Jacobs JJ; Keblusek P; Itahana K; Van Lohuizen M; Campisi J; Wazer DE; Band V Cancer Res; 2002 Aug; 62(16):4736-45. PubMed ID: 12183433 [TBL] [Abstract][Full Text] [Related]
9. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants. Inga A; Resnick MA Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991 [TBL] [Abstract][Full Text] [Related]
10. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Willis A; Jung EJ; Wakefield T; Chen X Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206 [TBL] [Abstract][Full Text] [Related]
11. High susceptibility of a human breast epithelial cell type with stem cell characteristics to telomerase activation and immortalization. Sun W; Kang KS; Morita I; Trosko JE; Chang CC Cancer Res; 1999 Dec; 59(24):6118-23. PubMed ID: 10626801 [TBL] [Abstract][Full Text] [Related]
12. Differential effects of p53 mutants on the growth of human bronchial epithelial cells. Coursen JD; Bennett WP; Khan MA; Forrester K; Pietenpol JA; Harris CC Mol Carcinog; 1997 Jul; 19(3):191-203. PubMed ID: 9254886 [TBL] [Abstract][Full Text] [Related]
13. Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. Katayose D; Gudas J; Nguyen H; Srivastava S; Cowan KH; Seth P Clin Cancer Res; 1995 Aug; 1(8):889-97. PubMed ID: 9816059 [TBL] [Abstract][Full Text] [Related]
14. Events in the immortalizing process of primary human mammary epithelial cells by the catalytic subunit of human telomerase. Kim H; Farris J; Christman SA; Kong BW; Foster LK; O'Grady SM; Foster DN Biochem J; 2002 Aug; 365(Pt 3):765-72. PubMed ID: 11978176 [TBL] [Abstract][Full Text] [Related]
15. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines. Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536 [TBL] [Abstract][Full Text] [Related]
16. Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. DiRenzo J; Signoretti S; Nakamura N; Rivera-Gonzalez R; Sellers W; Loda M; Brown M Cancer Res; 2002 Jan; 62(1):89-98. PubMed ID: 11782364 [TBL] [Abstract][Full Text] [Related]
17. Abrogation of p53 by its antisense in MCF-7 breast carcinoma cells increases cyclin D1 via activation of Akt and promotion of cell proliferation. Chhipa RR; Kumari R; Upadhyay AK; Bhat MK Exp Cell Res; 2007 Nov; 313(19):3945-58. PubMed ID: 17935714 [TBL] [Abstract][Full Text] [Related]
18. Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants. Deb D; Scian M; Roth KE; Li W; Keiger J; Chakraborti AS; Deb SP; Deb S Oncogene; 2002 Jan; 21(2):176-89. PubMed ID: 11803461 [TBL] [Abstract][Full Text] [Related]
19. Modulation of gene expression by tumor-derived p53 mutants. Scian MJ; Stagliano KE; Ellis MA; Hassan S; Bowman M; Miles MF; Deb SP; Deb S Cancer Res; 2004 Oct; 64(20):7447-54. PubMed ID: 15492269 [TBL] [Abstract][Full Text] [Related]
20. COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis. Zhou X; Wang XW; Xu L; Hagiwara K; Nagashima M; Wolkowicz R; Zurer I; Rotter V; Harris CC Cancer Res; 1999 Feb; 59(4):843-8. PubMed ID: 10029073 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]